District Of Columbia is currently home to 862 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Non Small Cell Lung Cancer, Lung Cancer, Breast Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
NCT02203903
Recruiting
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
Gender:
ALL
Ages:
Between 6 months and 80 years
Trial Updated:
05/29/2025
Locations: Childrens National Medical Center, Washington, District of Columbia
Conditions: Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
Register for Updates
Esprit BTK Post-Approval Study
NCT06656364
Recruiting
The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Washington Hospital Center, Washington, D.C., District of Columbia
Conditions: Chronic Limb-Threatening Ischemia
Register for Updates
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588
Recruiting
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: GSK Investigational Site, Washington, District of Columbia
Conditions: Neoplasms, Head and Neck
Register for Updates
The Effect of a Low-fat Vegan Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes
NCT06106035
Recruiting
The goal of this 16-week clinical trial is to assess the health benefits of a low-fat vegan diet on insulin sensitivity and glycemic control in type 2 diabetes. Participants will receive at no cost, study-related weekly nutrition education classes and one-on-one consultation with a registered dietitian.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Physicians Committee for Responsible Medicine, Washington, District of Columbia
Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 in Obese
Register for Updates
The CARING Study: Creating and Restoring Health Through Nutrition Guidance
NCT05795439
Recruiting
The CARING study assesses the health benefits of nutrition education for Blue Cross Blue Shield subscribers, as well as potential healthcare cost savings to subscribers and the insurance company.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Physicians Committee for Responsible Medicine, Washington, District of Columbia
Conditions: Type2diabetes, Type 2 Diabetes Treated With Insulin
Register for Updates
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
NCT01297400
Recruiting
To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Burns
Register for Updates
Addressing Genomic Disparities in Cancer Survivors
NCT06073626
Recruiting
The goal of this observational study is to increase genetic education and genetic testing for hereditary cancer risk among Black cancer survivors. The study will: 1. Test the effectiveness of a chatbot intervention (also called relational agent, or RA) vs. enhanced usual care (EUC) on engagement in genetic education and requests for genetic testing. 2. Evaluate the impact of the chatbot vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also calle... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/27/2025
Locations: Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Conditions: Hereditary Cancer, Genetic Testing
Register for Updates
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy and in combination with budigalimab, carboplatin, or cisplatin. ABBV-706 is an investigational drug being developed for the treatment of small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine carcinomas (NECs). There a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Georgetown University Hospital /ID# 255352, Washington, District of Columbia
Conditions: Advanced Solid Tumors
Register for Updates
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
NCT04835428
Recruiting
This is a multicenter, single-blinded, randomized controlled clinical trial evaluating the safety and efficacy of the AGN1 LOEP SV Kit for the treatment of painful vertebral compression fragility fractures (VCFs). The objective of this study is to demonstrate non-inferiority of the AGN1 LOEP SV Kit for the treatment of VCFs to standard of care vertebroplasty treatment using bipedicular injection of PMMA bone cement.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/27/2025
Locations: GW Medical Faculty Associates, Washington, District of Columbia
Conditions: Vertebral Compression Fracture, Compression Fracture, Vertebral Compression
Register for Updates
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
NCT02855476
Recruiting
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Gender:
ALL
Ages:
Between 11 years and 75 years
Trial Updated:
05/27/2025
Locations: Georgetown University, Washington, District of Columbia
Conditions: Huntington's Disease
Register for Updates
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
NCT06712875
Recruiting
Pediatric gliomas harboring BRAF-alterations, commonly BRAFV600 mutation or KIAA1549-BRAF fusion, are currently treated with either chemotherapy or mitogen activated protein kinase (MAPK) inhibitors, such as, dabrafenib and/or trametinib. Unfortunately, some BRAF-altered gliomas can progress or have rebound growth after discontinuation of therapy. Data from BRAFV600E-mutant melanoma has shown potential synergy between MAPK inhibition and anti-programmed cell death 1 (anti-PD1) checkpoint blockad... Read More
Gender:
ALL
Ages:
Between 1 year and 26 years
Trial Updated:
05/23/2025
Locations: Children's National Hospital, Washington DC, District of Columbia
Conditions: Low Grade Glioma, High Grade Glioma
Register for Updates